linjc16/ctgov huggingface dataset:
Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy

Study Overview
=================
Brief Summary
-----------------
Swelling of the prostate can occur during and after a brachytherapy. This swelling can cause urinary problems ranging from difficulty voiding to urinary retention. The purpose of this study is to investigate whether Mobicox started one week before brachytherapy and then continued afterwards is more effective in reducing the risk of needing a catheter than Mobicox given only afterwards.

Official Title
-----------------
A Comparison of 2 Schedules of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy - A Randomized Phase III Trial

Conditions
-----------------
Prostatic Neoplasms

Intervention / Treatment
-----------------
* Drug: Meloxicam


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligible to receive prostate brachytherapy as per the Ontario Provincial Guidelines will be eligible for this study (i.e. prostate specific antigen [PSA] < 10, Gleason score <7, Stage <= T2a) Exclusion Criteria: Patients already taking anti-inflammatory drugs Patients with allergic-type reactions, including asthma and urticaria, to aspirin or nonsteroidal anti-inflammatory agents (see product information)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Meloxicam|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare 2 schedules of MeloxicamTM given in the peri-operative period to reduce prostate swelling after permanent seed implantation for prostate cancer |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the influence of different timing of MeloxicamTM administration on urinary toxicity and biochemical response after permanent seed implantation for prostate cancer |  |  |
Sonographic Evaluation to Predict Difficult Airway Management

Study Overview
=================
Brief Summary
-----------------
the aim of this study was to evaluate the accuracy of different ultrasonographic parameters and clinical tests to predict difficult airway assessment. Ultrasonographic parameters were: hyo-mental distence, tongue width, skin to epiglottis distence and skin to hyoid bone distence. these parameters were recorded and their predictive acurracy was studied.

Detailed Description
-----------------
the aim of this study was to evaluate the accuracy of different ultrasonographic parameters and clinical tests to predict difficult airway assessment. Ultrasonographic parameters were: hyo-mental distence, tongue width, skin to epiglottis distence and skin to hyoid bone distence. these parameters were recorded and their predictive acurracy was studied. This study analyzed a sample size of 200 patients undergoing elective or urgent surgery under general anesthesia and recieving neuromuscular blocking agent before laryngoscopy. the correlation between ultrasonographic parameters and difficult laryngoscopy was studied

Official Title
-----------------
Sonographic Evaluation to Predict Difficult Airway Management

Conditions
-----------------
Airway Management, Upper Airway Sonographic Evaluation

Intervention / Treatment
-----------------
* Diagnostic Test: upper airway sonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients scheduled for orthopedic or viseral surgery under general anesthesia and tracheal intubation. Exclusion Criteria: patients with suspected tracheal stenosis Patients with a poor quality ultrasonographic exam

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| difficult laryngoscopy<br>group of patients with Cormack and Lehane grade III or IV | Diagnostic Test: upper airway sonography<br>* clinical evaluation of upper airway, ultrasonographic assessement<br>|
| easy laryngoscopy<br>group of patients with Cormack and Lehane grade I or II | Diagnostic Test: upper airway sonography<br>* clinical evaluation of upper airway, ultrasonographic assessement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prediction of difficult laryngoscopy with ultrasonographic criteria | incidence of difficult laryngoscopy | 5 min after induction of general anesthesia determined by Cormack and Lehane grade | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prediction of difficult mask ventilation with ultrasonographic criteria | Incidence of difficult ventilation | 3 min after induction of general anesthesia |
Effect of PTH(1-34) Treatment on Fracture Healing in Vivo

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate, whether PTH(1-34) is able to promote fracture healing in postmenopausal women with fractures of the hip or shoulder.

Official Title
-----------------
Effect of PTH(1-34) Treatment on Fracture Healing in Vivo

Conditions
-----------------
Shoulder Fractures, Trochanteric Fractures

Intervention / Treatment
-----------------
* Drug: rhPTH(1-34)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute new osteoporotic trochanteric or collum chirurgicum fracture Postmenopause Exclusion Criteria: Calcium metabolic disease other than osteoporosis Diseases known to affect calcium homeostasis Dementia Hypersensitivity to drug or other components of medication pre-existing hypercalcemia Decreased kidney function Increased alkaline phosphatase Prior external radiation therapy or brachytherapy of the skeleton Skeletal malignancies or bone metastases Alcohol and/or drug abuse Systemic treatment with corticosteroids within the last four weeks Non-cooperating patients Patients who do not speak and understand the danish language

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Femur PTH(1-34)<br>24 participants with trochanteric fractures will be assigned to Forsteo (PTH(1-34)) treatment | Drug: rhPTH(1-34)<br>* Injection of 20 micrograms per day in eight weeks<br>* Other names: Teriparatide;|
| No Intervention: Femur Control<br>24 participants with trochanteric fractures will be assigned to no treatment | |
| Experimental: Humerus PTH(1-34)<br>24 participants with collum chirurgicum fracture will be assigned to Forsteo (PTH(1-34)) treatment | Drug: rhPTH(1-34)<br>* Injection of 20 micrograms per day in eight weeks<br>* Other names: Teriparatide;|
| No Intervention: Humerus Control<br>24 participants with collum chirurgicum fracture will be assigned to no treatment. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiological evaluation of healing |  | 0, 4, 8, 12, (16) weeks after fracture | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biochemical bone markers |  | 0, 1, 2, 3, 4, 8, 12, (16) weeks after fracture | 
| SF-36 questionnaire |  | 0, 4, 8, 12, (16) weeks after fracture | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fracture, Osteoporosis, Forsteo, Teriparatide, Fracture healing
Comparison Between 2 Doses of Misoprostol Before Intrauterine Device

Study Overview
=================
Brief Summary
-----------------
The purpose of the investigators' study was to evaluate whether misoprostol will improve pain scores .

Detailed Description
-----------------
an intrauterine device can cause pain and discomfort in several ways: Use of the tenaculum to grasp the cervix and straighten the uterus for proper insertion; trans-cervical actions including measuring uterine depth, inserting the intrauterine device insertion tube, and removing the tube; and placement of the device in the uterus.

Official Title
-----------------
Comparison Between 2 Different Doses of Vaginal Misoprostol Before Intrauterine Device Insertion in Parous Women

Conditions
-----------------
Pain Relief

Intervention / Treatment
-----------------
* Drug: misoprostol 200
* Drug: misoprostol 400


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Women not taken analgesics or anxiolytics in the 24 hours prior insertion Women who will accept to participate in the study Exclusion Criteria: Any contraindication to IUD placement

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: misoprostol 200<br>misoprostol 200 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted | Drug: misoprostol 200<br> <br> |
| Active Comparator: misoprostol 400<br>misoprostol 400 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted | Drug: misoprostol 400<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean pain score during intrauterine device insertion |  | 5 minutes |
The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy

Study Overview
=================
Brief Summary
-----------------
This project aims to: 1) evaluate the long-term effectiveness of telemedicine to detect diabetic retinopathy when compared to traditional surveillance methods, 2) identify the health belief factors related to adherence with annual diabetic eye exams, and 3) determine the cost-effectiveness of the telemedicine system from the perspective of the community clinic, the third-party payer, and the individual patient.

Official Title
-----------------
The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy

Conditions
-----------------
Diabetic Retinopathy

Intervention / Treatment
-----------------
* Procedure: Ophthalmic Telemedicine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diabetic, at least 18 years old, patient at a participating health clinic

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Telemedicine<br>Participants in this group have digital images of their retina captured with a non-mydriatic camera and are encouraged to see an eye care provider yearly. | Procedure: Ophthalmic Telemedicine<br>* Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.<br>|
| No Intervention: Traditional Surveillance<br>Participants in this group are encouraged to see an eye care provider each year for a diabetic eye exam. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of Participants that Receive Annual Eye Exam | This outcome measure will be used to determine (1) whether the telemedicine system increases the proportion of participants that receive an annual eye exam, and (2) what health belief factors are associated with adherence. | Baseline; Change from Baseline at 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years (number of follow-up exams depends on number of years enrolled in the study) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes, Diabetic Retinopathy Screening, Ophthalmic Telemedicine, Comparative Effectiveness Research
Cholecalciferol on Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
Screening the prevalence of vitamin D deficiency among Egyptian hemodialysis patients on a single center (Ain Shams University hospital). Assessing the effect of the native type of vitamin D (Cholecalciferol) on replenishing its deficiency via extra-renal vitamin D receptors (VDR), among Egyptian hemodialysis patients. Assessing the effect of cholecalciferol on vascular calcification among Egyptian hemodialysis patients. Assessing the effect of cholecalciferol on Blood pressure, parathyroid hormone.

Official Title
-----------------
Effect of Cholecalciferol on Hemodialysis Patients

Conditions
-----------------
Hemodialysis Complication, Vitamin D Deficiency, Vascular Calcification

Intervention / Treatment
-----------------
* Drug: Cholecalciferol
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both sexes aged between 18-75 years Patients on HD greater than 3 months at least. Stable clinical condition (no hospitalization in the previous 3 months) Informed consent in accordance with the Declaration of Helsinki. PTH level between 150 - 800 pg/ml. Exclusion Criteria: Hypersensitivity to cholecalciferol. Participant in an another clinical trial within the past 4 weeks. Judged to be unsuitable as a subject by the attending physician. Pregnant or breastfeeding female

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Drug Group<br>twenty-five patients will receive 200.000 IU/month native vitamin D; (Cholecalciferol) orally in addition to their standard treatment for 3 months period | Drug: Cholecalciferol<br>* Native vitamin D dose of 200IU to be given once per month to hemodialysis patients<br>* Other names: Native vitamin D;|
| Placebo Comparator: Placebo Group<br>twenty-five patients will receive a placebo ampule with their standard treatment for 3 months period. | Drug: Placebo<br>* A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vitamin D level | Target serum Vitamin D level ≥ 30 ng/ml | 3 months |
Associations Between Vision and Brain Function

Study Overview
=================
Brief Summary
-----------------
Case-control studies and meta-analysis have reported that several ocular features, especially the thickness of the peripapillary retinal nerve fiber layer and visual acuity, are related to the brain degeneration and cognitive impairment. In our study, we aim to quantitatively assess ocular features using structural and functional indicators and define its associations with brain development and intelligence in children.

Official Title
-----------------
Quantitative Assessment of the Vison Using Structural and Functional Indicators and Associations With Brain Function

Conditions
-----------------
Healthy, Vision; Disorder, Loss

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age from 3 to 12 years old Exclusion Criteria: diagnosed with nervous system disease before

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy group<br> | |
| Mild visual impairment group<br> | |
| Moderate and severe visual impairment group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the visual information processing function | collected with the electroencephalogram | recorded at enrollment | 
| best corrected visual acuity | collected with visual acuity chart | recorded at enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| refractive status | the refractive status of both eyes | recorded at enrollment | 
| intraocular pressure | the intraocular pressure of both eyes | recorded at enrollment | 
| fundus picture | the fundus pictures of both eyes | recorded at enrollment |
GAT-DCT-Discordance Due to Corneal Properties

Study Overview
=================
Brief Summary
-----------------
IOP is measured with two devices (Dynamic Contour Tonometry (DCT) and Goldmann applanation tonometry (GAT)).

Detailed Description
-----------------
DCT reading will be compared to a corrected GAT reading by the formula of Elsheikh, Alhasso and Pye. Trial with medical device

Official Title
-----------------
Influence of Discordant Intraocular Eye Pressure Readings Taken by Dynamic Contour Tonometry and Goldmann Applanation Tonometry

Conditions
-----------------
Glaucoma

Intervention / Treatment
-----------------
* Device: Intraocular Pressure Measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: clinical diagnosis of glaucoma Exclusion criteria: other optic neuropathy other then glaucoma age<18 corneal surgery use of contact lenses

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Intraocular Pressure Measurement|Intraocular pressure is measured with GAT and with DCT|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraocular pressure (IOP) | IOP is measured with goldman-applanation tonometer and dynamic-contour-tonometer at the only study visit (V0) | IOP is measured at the only study visit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographical and clinical data | Age, axial length of the eye, central corneal thickness | study visit V0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma, Goldmann Tonometry, Dynamic Contour Tonometry
Assessment of the Internal Urethral Sphincter and the Vagina by Three Dimensional Ultrasound

Study Overview
=================
Brief Summary
-----------------
Continent women have an intact internal urethral sphincter that extends from the bladder neck down to the perineal membrane. The internal urethral sphincter is a strong collagen muscle tissue cylinder lined by urothelium. On ultrasound scanning tissue echo will be detected torn internal urethral sphincter will not stand sudden rise of abdominal pressure. Three dimensional ultrasound assessment of the internal urethral sphincter is very sensitive and specific for the diagnosis of stress urinary incontinence.

Detailed Description
-----------------
The internal urethral sphincter used to be said it's a muscular ring but the investigators will visualize by three dimensional ultrasound it's a cylinder in shape and it's the cause of stress urinary incontinence by being torn by stretching the vagina during normal delivery.

Official Title
-----------------
Ultrasonic Assessment of the Urethra and the Vagina in Normal Continent Women and Women Suffering From Stress Urinary Incontinence

Conditions
-----------------
Urinary Incontinence Due to Urethral Sphincter Incompetence

Intervention / Treatment
-----------------
* Device: ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: signed an informed consent patient with stress urinary incontinence patient have done a vaginal delivery patient with genital prolapse Exclusion Criteria: refusal to sign an informed consent patient have urinary tract infection patient with pregnancy patient have vaginal infection patient who has undiagnosed vaginal bleeding
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| stress urinary incontinence<br>group 1 women with stress urinary incontinence by ultrasonography | Device: ultrasonography<br>* open<br>* Other names: transvaginal probe;|
| continent group<br>group 2 women without stress urinary incontinence by ultrasonography | Device: ultrasonography<br>* open<br>* Other names: transvaginal probe;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluation of the internal urethral sphincter and assesst the extend and degree of the torn internal urethral sphincter | we are going to do 3d ultrasound by transvaginal probe to see the internal urethral sphincter if torn or not and evaluate the morphology of the urethra and pelvic floor structure | 6 month |